Clinical Trials Browser

Active not recruiting × Interventional × Drug Therapy × Clear all

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT02392429 2026-04-13

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Active not recruiting

87 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT05710328 2026-04-03

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05763199 2026-03-12

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Phase NA Active not recruiting

Breast Neoplasms

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT04928807 2026-02-27

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Phase 3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05421897 2026-01-29

RAPID

Phase 1 Active not recruiting

Neoplasms, Neuroblastoma

NCT03210103 2026-01-28

ORATOR2

Phase NA Active not recruiting

Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT07339488 2026-01-14

ILDR-03

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT02454543 2026-01-12

g-RAMPP

Phase NA Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT03599752 2026-01-09

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07306663 2025-12-29

ESO-Nanjing7

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT02153229 2025-12-26

MPM-PDT

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05111626 2025-12-15

FORTITUDE-102

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02866136 2025-11-24

RETINO2011

Phase 2 Active not recruiting

Other solid neoplasm

Retinoblastoma, Retinal Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Phase 3 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT02994069 2025-10-14

Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers

Phase 2 Active not recruiting

80 enrolled 11 charts

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04888312 2025-10-08

OPTIMIZE-1

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT03283384 2025-09-19

NEOLBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT03721341 2025-09-18

SABR-COMET 10

Phase 3 Active not recruiting

Neoplasm Metastasis

NCT07145333 2025-09-08

Drug-SNP

Phase 2/3 Active not recruiting

SCLC

NCT03070366 2025-09-02

OMET

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04046133 2025-08-05

CORINTH

Phase 1 Active not recruiting

Gastrointestinal

Anus Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01064466 2025-07-24

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Small Cell Lung Carcinoma

NCT04905316 2025-06-17

CHORUS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06922279 2025-05-11

SOCRATE

Phase NA Active not recruiting

Gastrointestinal

Gastroesophageal Cancer (GC)

NCT06190600 2025-04-30

SPORTNATHy

Phase NA Active not recruiting

Breast Neoplasms, Motor Activity

NCT06946420 2025-04-27

SENECA

Phase 3 Active not recruiting

Gastrointestinal

Radiation Therapy

NCT00938145 2025-04-11

3 Tesla MRI in Patients With Bladder Cancer

Phase NA Active not recruiting

Urinary Bladder Neoplasms

NCT03930498 2025-01-28

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04722848 2025-01-23

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02843191 2024-12-27

Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Phase 3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06727357 2024-12-10

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

Phase 2 Active not recruiting

Breast Neoplasms

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT03018418 2024-09-19

Proton Therapy in Reducing Toxicity in Anal Cancer

Phase 2 Active not recruiting

14 enrolled 14 charts

Gastrointestinal

Anus Neoplasms